Acute Liver Failure
56
5
8
21
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.4%
3 terminated out of 56 trials
87.5%
+1.0% vs benchmark
7%
4 trials in Phase 3/4
29%
6 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (56)
Etiology and Prognostic Factors in Patients With Acute Liver Failure
TReatment for ImmUne Mediated PathopHysiology
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF
Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure
F573 for Injection for the Treatment of Liver Injury/Failure
Longitudinal Study of Mitochondrial Hepatopathies
High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema
CytOSorb TreatMent Of Critically Ill PatientS Registry
Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis
Biomarkers in Liver Failure
Continuous Renal Replacement Therapy Intensity in Hyperammonemia
Clinical Study of Pediatric Acute Liver Failure
Plasma Exchange for Amanita Toxin-induced Acute Liver Failure
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure
Etiology and Prognostic Analysis of Acute Liver Failure in Chinese Children
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
Prevention of Recurrent Hepatitis B After Liver Transplantation
Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis